




The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 134% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 59% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	4,309
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	314
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,490
Other Liabilities	0
Other Net Income	19
Other Revenues	0
Property and Equipment	0
Research and Development	898
Selling, General and Administrative Expense	1,718

Output Variable	Value in 1000 USD
Assets	4,309
Liabilities	314
Expenses	5,106
Revenues	0
Stockholders Equity	3,995
Net Income	-5,087
Comprehensive Net Income	-5,087
BaseVar	4,874
ECR before LimitedLiability	157%
Economic Capital Ratio	273%